Form 4: Globus Medical CEO Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Globus Medical CEO Daniel T. Scavilla exercised stock options and sold 130,000 shares of Class A Common Stock on November 21, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On November 21, 2024, Daniel T. Scavilla, the CEO of Globus Medical Inc., exercised options to acquire 130,000 shares of Class A Common Stock.
- The options were exercised at prices of $43.77 and $43.58 per share for 50,000 and 80,000 shares respectively.
- Following the exercise of these options, Mr. Scavilla sold 130,000 shares of Class A Common Stock at a price of $85 per share.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan established on June 7, 2024.
- The exercised options were granted on January 22, 2018 and January 22, 2019, and were fully vested.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction by an executive, with no indication of positive or negative sentiment. It is a standard SEC filing.
Industry Context
This is a routine filing related to insider transactions. It is common for executives to exercise stock options and sell shares, often under pre-arranged trading plans to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a standard practice among public company executives to manage their personal finances while avoiding potential insider trading issues.
- The exercise of stock options and subsequent sale of shares is a common occurrence for executives in publicly traded companies, particularly those with equity-based compensation.
- The prices at which the options were exercised and the shares were sold are within the typical range for such transactions, reflecting the market value of the company's stock at the time.
Stakeholder Impact
- The sale of shares by the CEO may have a minor impact on the stock price, but it is unlikely to be significant given the pre-arranged nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 01/22/2018 | Date when 50,000 stock options were granted. |
| 01/22/2019 | Date when 80,000 stock options were granted. |
| 06/07/2024 | Date the Rule 10b5-1 trading plan was established. |
| 11/21/2024 | Date of the stock option exercise and share sale. |
| 11/25/2024 | Date the SEC Form 4 was signed. |
| 01/22/2028 | Expiration date of the 50,000 stock options. |
| 01/22/2029 | Expiration date of the 80,000 stock options. |
Keywords
Globus Medical, GMED, Daniel T. Scavilla, Stock Options, Rule 10b5-1, Insider Trading, SEC Form 4, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.